share_log

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/11/13 00:41

牛牛AI助理已提取核心訊息

Addex Therapeutics reported a provisional net loss of CHF 1.5 million for Q3 2024, compared to a net profit of CHF 12.9 million in Q2 2024. The CHF 14.4 million decrease is primarily attributed to a non-recurring CHF 14.0 million gain from the sale of part of Addex's business to Neurosterix in Q2. The company expects to generate quarterly losses in the future.Despite the Q3 loss, Addex's nine-month results remain positive with a net profit of CHF 8.3 million, down from CHF 9.8 million for the six-month period ended June 30, 2024. The cash position stood at CHF 3.3 million as of September 30, 2024. Final Q3 and nine-month results are still under review and may be subject to change.Addex will release its full Q3 2024 Financial Results on November 22, 2024, followed by a teleconference and webcast for investors, analysts, and media at 16:00 CET. The company continues to focus on developing novel small molecule allosteric modulators for neurological disorders, with its lead candidate dipraglurant under evaluation for brain injury recovery.
Addex Therapeutics reported a provisional net loss of CHF 1.5 million for Q3 2024, compared to a net profit of CHF 12.9 million in Q2 2024. The CHF 14.4 million decrease is primarily attributed to a non-recurring CHF 14.0 million gain from the sale of part of Addex's business to Neurosterix in Q2. The company expects to generate quarterly losses in the future.Despite the Q3 loss, Addex's nine-month results remain positive with a net profit of CHF 8.3 million, down from CHF 9.8 million for the six-month period ended June 30, 2024. The cash position stood at CHF 3.3 million as of September 30, 2024. Final Q3 and nine-month results are still under review and may be subject to change.Addex will release its full Q3 2024 Financial Results on November 22, 2024, followed by a teleconference and webcast for investors, analysts, and media at 16:00 CET. The company continues to focus on developing novel small molecule allosteric modulators for neurological disorders, with its lead candidate dipraglurant under evaluation for brain injury recovery.
Addex Therapeutics報告2024年第三季度臨時淨虧損150萬瑞士法郎，而2024年第二季度的凈利潤爲1290萬瑞士法郎。1400萬瑞士法郎的減少主要是由於在第二季度將部分Addex業務出售給Neurosterix所帶來的一次性收益。公司預計未來將產生季度虧損。儘管第三季度出現虧損，Addex的九個月業績仍然積極，凈利潤爲830萬瑞士法郎，低於截至2024年6月30日的六個月期間的980萬瑞士法郎。截至2024年9月30日，現金位置爲330萬瑞士法郎。最終的第三季度和九個月業績仍在審查中，可能會有所變動。Addex將在2024年11月22日發佈完整的2024年第三季度財務業績，隨後將在16:00 CEt爲投資者、分析師和媒體舉辦電話會議和網絡直播。公司繼續專注於開發用於神經系統疾病的創新小分子變構調節劑，其主導候選藥物dipraglurant正在評估用於腦損傷恢復。
Addex Therapeutics報告2024年第三季度臨時淨虧損150萬瑞士法郎，而2024年第二季度的凈利潤爲1290萬瑞士法郎。1400萬瑞士法郎的減少主要是由於在第二季度將部分Addex業務出售給Neurosterix所帶來的一次性收益。公司預計未來將產生季度虧損。儘管第三季度出現虧損，Addex的九個月業績仍然積極，凈利潤爲830萬瑞士法郎，低於截至2024年6月30日的六個月期間的980萬瑞士法郎。截至2024年9月30日，現金位置爲330萬瑞士法郎。最終的第三季度和九個月業績仍在審查中，可能會有所變動。Addex將在2024年11月22日發佈完整的2024年第三季度財務業績，隨後將在16:00 CEt爲投資者、分析師和媒體舉辦電話會議和網絡直播。公司繼續專注於開發用於神經系統疾病的創新小分子變構調節劑，其主導候選藥物dipraglurant正在評估用於腦損傷恢復。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間